Nova Leap Health Corp.
NVLPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | -0.02 | 0.46 | -0.01 |
| FCF Yield | 2.11% | 3.50% | 1.25% | 1.80% |
| EV / EBITDA | 26.23 | -73.54 | 88.29 | 14.56 |
| Quality | ||||
| ROIC | 1.40% | 1.34% | 0.36% | 0.87% |
| Gross Margin | 39.60% | 40.19% | 39.00% | 39.09% |
| Cash Conversion Ratio | 1.10 | -1.26 | -2.51 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.30% | 1.35% | -1.09% | -3.01% |
| Free Cash Flow Growth | -23.05% | 211.01% | -37.28% | 9.21% |
| Safety | ||||
| Net Debt / EBITDA | 1.59 | -7.13 | 9.97 | 0.88 |
| Interest Coverage | 5.00 | 3.29 | 0.93 | 4.89 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -10.66 | -11.73 | -11.43 | -9.31 |